Search Results
Case report highlights TED after COVID-19 vaccine in patient with Graves’ Disease history
In this case report, a 50-year-old woman presented with periorbital swelling and proptosis that had lasted for 2 months and...
Read MoreTED severely impacts quality of life even when disease is stable
Even after acute thyroid eye disease (TED) symptoms have subsided, patients still feel the physical and psychosocial impacts of the...
Read MoreFrom supportive therapy to disease-modifying: How the management of TED has changed
With the 2020 approval of teprotumumab (Tepezza; Horizon Therapeutics), the treatment and management of thyroid eye disease (TED) has been...
Read MoreAs women are at higher risk for eye disease, Prevent Blindness declares April as Women’s Eye Health and Safety Month
Two out of every three people living with blindness or vision problems are women, according to the National Eye Institute. And,...
Read MoreThermal imaging useful in eyes with subtle clinical signs of TED
Surface inflammation in patients with thyroid eye disease (TED) can be detected with thermal imaging, according to a study. In...
Read MoreLong-term recurrence of eyelid retraction after surgical correction more common in upper eyelid
In this retrospective review, 60 patients (133 eyelids) who underwent eyelid-lengthening procedures for the correction of thyroid eye disease-associated upper...
Read MoreLonger disease duration doesn’t seem to impact teprotumumab response in TED
Data from the OPTIC phase 3, 24-week randomized, double-masked, placebo-controlled treatment trial was used to assess long-term proptosis response in...
Read MoreNew data on teprotumumab in the less severe eye of patients with TED to be presented at AAO 2020 Virtual
New data on teprotumumab (Tepezza, Horizon Therapeutics) in the less severe eye of patients with Thyroid Eye Disease (TED) will...
Read MoreStudy finds limited incidence of glycemic excursions in patients with TED treated with teprotumumab
Serious glycemic excursions are uncommon in patients with thyroid eye disease (TED) who receive teprotumumab therapy, particularly in those who...
Read MoreNeuroimaging markers could aid in early detection of immune-related visual dysfunction in TED
Combined orbital and brain neuroimaging showed abnormalities of the visual processing system (VPS) in thyroid eye disease (TED), which had...
Read MoreOrbital decompression does not affect outcome of rectus muscle recession surgery in patients with TED
Prior orbital decompression does not have a significant effect on the outcomes of rectus muscle recession surgery in patients with...
Read MorePresentation talks prevalence of hearing-related issues in TED patients treated with teprotumumab
There is a lack of independent data on the prevalence of hearing-related issues in thyroid eye disease (TED) patients and...
Read MoreTED shows unimodal age distribution, peaking at younger ages in certain races
A detailed overview of thyroid eye disease (TED), including new insights like a single-peak age distribution and variations in prevalence...
Read More
Contact Info
